Insight

Alizée Camps Maléa and Cédric Draulans

Oct 12, 2024, 19:36

5 Year Results of the Hypo-FLAME Trial

Alizée Camps Maléa, Radiation oncologist at Gustave Roussy and President of the French Society of Young Radiation Oncologists at SFjRO, shared a recent article by Cédric Draulans, Scientific Researcher in Radiation Oncology at KU Leuven, on X:

“Hypo-FLAME phase 2.

Intermediate & high-risk prostate cancer.

SBRT 35 Gy to the whole prostate gland in 5 weekly fractions & focal boosts to the intraprostatic tumor 50 Gy.

5-year: bDFS 93% & grade 2+ tox GU 12% GI 4%.”

Stereotactic body radiotherapy with a focal boost to the intraprostatic tumor for intermediate and high risk prostate cancer: 5-year efficacy and toxicity in the hypo-FLAME trial

Authors: Cédric Draulans, Karin Haustermans, Floris J. Pos, Uulke A. van der Heide, Lisa De Cock, Jochem van der Voort van Zyp, Hans De Boer, Robert J. Smeenk, Martina Kunze-Busch, Evelyn M Monninkhof, Sofie Isebaert and Linda G.W. Kerkmeije

cancer Cédric Draulans Evelyn M. Monninkhof Floris J. Pos Gustave Roussy hypo-FLAME trial intraprostatic tumor Karin Haustermans KU Leuven Linda G.W. Kerkmeije Martina Kunze-Busch OncoDaily oncologyu prostate cancer radiotherapy Robert J. Smeenk SFjRO Sofie Isebaert Uulke A. van der Heide

Bispecific Antibody M701 Offers a Novel Treatment Option for Malignant Ascites

Giuliana Rancic and Breast Cancer: How She Went Against, How She Survived, and More

Vincent Rajkumar: Paradigm changing AQUILA randomized trial in high risk smoldering myeloma

"The Doctor Who Always Has Candies in His Pocket": A Conversation with Professor Guangchao Zhang, Pioneer of Pediatric Surgical Oncology in China

Wanda Sykes and Breast Cancer: How She Went Against, How She Survived, and More

Special Coverage